Langsung ke konten

Penyakit Sel Sabit (Anak-Anak)

Penanganan Anemia

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (terbuka di window baru)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Sumber‎: Lancet Haematol. 2023 ;10(4):e261-71.

Index‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (terbuka di window baru)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (terbuka di window baru)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Sumber‎: Acta Haematol 1995;94(3):128-34.

Index‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (terbuka di window baru)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (terbuka di window baru)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Sumber‎: Haematologica 2006;91(8):1076-83.

Index‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (terbuka di window baru)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (terbuka di window baru)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Sumber‎: J Obstet Gynaecol 2007;27(1):82-3.

Index‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (terbuka di window baru)